Marla Persky Net Worth

The estimated Net Worth of Marla Persky is at least $185 Mille dollars as of 14 November 2023. Ms. Persky owns over 6,370 units of Xeris Biopharma Inc stock worth over $18,218 and over the last 6 years she sold XERS stock worth over $0. In addition, she makes $166,360 as Independent Director at Xeris Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Persky XERS stock SEC Form 4 insiders trading

Marla has made over 1 trades of the Xeris Biopharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 6,370 units of XERS stock worth $10,065 on 14 November 2023.

The largest trade she's ever made was buying 6,370 units of Xeris Biopharma Inc stock on 14 November 2023 worth over $10,065. On average, Marla trades about 796 units every 0 days since 2019. As of 14 November 2023 she still owns at least 6,370 units of Xeris Biopharma Inc stock.

You can see the complete history of Ms. Persky stock trades at the bottom of the page.

Marla Persky biography

Marla S. Persky J.D. serves as Independent Director of the Company. Ms. Persky has served on our board of directors since April 2018. Since 2014, Ms. Persky has served as the chief executive officer and president of WOMN, LLC, a consulting and coaching organization. From 2005 to 2013, Ms. Persky was senior vice president, general counsel and corporate secretary of Boehringer Ingelheim Corporation, a pharmaceutical company. Ms. Persky also serves on the board of advisors of Text IQ, Inc. and the board of directors of Ygeia Group, Inc. Ms. Persky has a B.S.S. degree in speech sciences from Northwestern University and a J.D. from Washington University School of Law.

What is the salary of Marla Persky?

As the Independent Director of Xeris Biopharma Inc, the total compensation of Marla Persky at Xeris Biopharma Inc is $166,360. There are 9 executives at Xeris Biopharma Inc getting paid more, with Paul Edick having the highest compensation of $4,307,640.

How old is Marla Persky?

Marla Persky is 64, she's been the Independent Director of Xeris Biopharma Inc since 2018. There are 2 older and 17 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.

What's Marla Persky's mailing address?

Marla's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.

Insiders trading at Xeris Biopharma Inc

Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... e Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.

What does Xeris Biopharma Inc do?

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Complete history of Ms. Persky stock trades at Xeris Biopharma Inc

Xeris Biopharma Inc executives and stock owners

Xeris Biopharma Inc executives and other stock owners filed with the SEC include:

• Paul Edick,
  Chairman of the Board, Chief Executive Officer
• John Shannon,
  President, Chief Operating Officer
• Paul R. Edick,
  Chairman & CEO
• Barry Deutsch,
  Chief Financial Officer
• John P. Shannon,
  Pres, COO & Director
• Beth Hecht,
  Senior Vice President, General Counsel, Corporate Secretary
• Beth P. Hecht J.D.,
  Sr. VP, Gen. Counsel, Corp. Sec. & Director
• John Schmid,
  Lead Independent Director
• BJ Bormann,
  Independent Director
• Marla Persky,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• Dawn Halkuff,
  Independent Director
• Mark Thierer,
  Independent Director
• Kenneth Johnson,
  Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
• Steven Prestrelski,
  Co-Founder, Chief Scientific Officer
• Dr. Steven J. Prestrelski MBA, Ph.D.,
  Co-Founder & Chief Scientific Officer
• Kevin McCulloch,
  Sr. VP of Global Operations & Bus. Devel.
• Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
  Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs
• Barry M. Deutsch,
  Exec. Officer
• Allison Wey,
  Sr. VP of Investor Relations & Corp. Communications
• Steven M. Pieper,
  Chief Financial Officer
• Dr. Steven J. Prestrelski,
  Co-Founder & Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt L.P....,
  
• Partners, Ltd.Palmetto Part...,
  
• Barbara Jean Anne Bormann K...,
  Director
• Jonathan Rigby,
  Director
• Kevin Mc Culloch,
  See Remarks
• Steven Pieper,
  See Remarks
• John Johnson,
  Director
• Garheng Kong,
  Director
• Ricki Louise Fairley,
  Director